PRQR
ProQR Therapeutics N.V

4,321
Mkt Cap
$162.26M
Volume
144,699.00
52W High
$3.10
52W Low
$1.07
PE Ratio
-3.39
PRQR Fundamentals
Price
$1.54
Prev Close
$1.59
Open
$1.63
50D MA
$1.62
Beta
0.88
Avg. Volume
338,355.97
EPS (Annual)
-$0.452
P/B
2.74
$120.67
Loading...
Loading...
News
all
press releases
Q2 Earnings Estimate for PRQR Issued By HC Wainwright
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of ProQR Therapeutics in a report released on Monday, March...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Brokers Issue Forecasts for PRQR Q1 Earnings
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a note issued to...
MarketBeat·5d ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·8d ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus...
MarketBeat·9d ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer
Oppenheimer started coverage on ProQR Therapeutics in a report on Thursday. They set an "outperform" rating and a $9.00 price objective on the stock...
MarketBeat·10d ago
News Placeholder
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -30.80% and -2.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -31.21% and +47.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, Marketbeat reports...
MarketBeat·15d ago
News Placeholder
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday
ProQR Therapeutics (NASDAQ:PRQR) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...
MarketBeat·17d ago
<
1
2
...
>

Latest PRQR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.